ArticleCancer chemotherapy and pharmacology2018

Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model.

Andrea Gruber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.